Company intelligence / Profile preview
Progeneer
Not specified directly in sources*, Seoul Special City or Gyeonggi-do region*, South Koreaprogeneer.com ↗
- Ownership
- Private
- Employees
- ~33
- Development stage
- Preclinical
01
Overview
Progeneer is developing next-generation immunotherapies and vaccines leveraging its proprietary TLR7/8 agonist adjuvant and cell-free protein synthesis platforms. The company has demonstrated strong preclinical results in mounting cell-mediated immune responses with low toxicity, particularly for cancer and infectious disease indications. Clinical trials are being prepared but have not yet commenced as of 2025.[1][2][3]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinesImmunotherapiesAdjuvantsCell-free protein synthesis biologics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
FUJIFILM Pharmaceuticals U.S.A. Inc.HLB Biostep
Beyond the preview
Go deeper on Progeneer.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Progeneer.